Esperovax, founded in Plymouth, MI, is a biotechnology company dedicated to developing mRNA therapies. Its core mission is to combat the world's most devastating diseases through innovative oral mRNA vaccines. The company's vision is to revolutionize vaccine delivery by making it more accessible and effective. Esperovax focuses on creating targeted oral vaccines, which offer a non-invasive alternative to traditional injection-based methods.

Notable figures affiliated with Esperovax include Dr. Robin Robinson, who serves as President and CEO. The company has achieved significant milestones, such as being awarded $1 million for the development of an oral COVID-19 RNA vaccine under the HHS Project NextGen Initiative. Esperovax's work has the potential to significantly impact global health by providing easier and more efficient vaccine distribution methods.